WithdrawnPhase 2NCT03780166

A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris

Studying Pemphigus vulgaris

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Incyte Corporation
Principal Investigator: Kathleen Butler, MD
Incyte Corporation
Intervention: Parsaclisib(drug)
Eligibility: 18-80 years · All sexes
Timeline: 2019 – 2020

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03780166 on ClinicalTrials.gov

Other trials for Pemphigus vulgaris

Additional recruiting or active studies for the same condition.

RECRUITINGNCT07384221
Periodontal Status and Disease Severity in Pemphigus Vulgaris Patients
Saglik Bilimleri Universitesi
RECRUITINGPHASE1, PHASE2NCT04422912
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Cabaletta Bio
RECRUITINGNCT02753777
Autoimmune Blistering Diseases Study
University of Pennsylvania

See all trials for Pemphigus vulgaris →

← Back to all trials